Novel mutational and pathway signatures in relapsed/refractory colorectal cancer patients.

被引：0
|
作者：
Johnson, Benny
Cooke, Laurence
Mahadevan, Daruka
机构：
[1] Univ Tennessee, Ctr Hlth Sci, West Canc Ctr, Memphis, TN 38163 USA
[2] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA
[3] West Canc Ctr, Memphis, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.591
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
591
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Serum Ferritin as a Prognostic Biomarker for Survival in Relapsed or Refractory Metastatic Colorectal Cancer
    Lee, Sookyung
    Song, Anna
    Eo, Wankyu
    JOURNAL OF CANCER, 2016, 7 (08): : 957 - 964
  • [42] Novel treatment approaches for patients with relapsed and refractory multiple myeloma
    Sinha R.
    Lonial S.
    Current Treatment Options in Oncology, 2006, 7 (3) : 246 - 257
  • [43] Dose Escalation Study of GCC19CART CoupledCAR ® Technology for Patients with Relapsed or Refractory Colorectal Cancer
    Chen, Naifei
    Pu, Chengfei
    Zhao, Lingling
    Wang, Chang
    Zhu, Ruihong
    Liang, Tingting
    Huang, Xi
    Tang, Haiyang
    Wang, Yizhuo
    Jia, Beibei
    Chen, Dongqi
    Kennedy, Eugene
    Wu, Zhao
    Xiao, Lei
    Cui, Jiuwei
    BLOOD, 2021, 138
  • [44] Regorafenib in Patients With Relapsed Advanced or Metastatic Colorectal Cancer
    Bekaii-Saab, Tanios S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (09) : 10 - 11
  • [45] Genomic Landscape Including Novel Mutational Drivers in Relapsed/ Refractory Diffuse Large B Cell Lymphoma
    Wenzl, Kerstin
    Ortiz, Maria
    Stong, Nicholas
    Huang, C. Chris
    Maurer, Matthew J.
    Towfic, Fadi
    Hagner, Patrick R.
    Nikbakht, Hamid
    Stokes, Matthew
    Lata, Sneh
    Kamalakaran, Sitharthan
    Mavrommatis, Konstantinos
    Trotter, Matthew
    King, Rebecca L.
    Link, Brian K.
    Slager, Susan L.
    Asmann, Yan
    Czuczman, Myron
    Ansell, Stephen M.
    Habermann, Thomas M.
    Cerhan, James R.
    Nowakowski, Grzegorz
    Novak, Anne J.
    Gandhi, Anita K.
    BLOOD, 2019, 134
  • [46] A phase 1 trial of ruxolitinib, lenalidomide, and methylprednisolone for relapsed/refractory multiple myeloma patients.
    Berenson, James R.
    To, Jennifer
    Spektor, Tanya M.
    Turner, Carley
    Swift, Regina A.
    Eades, Benjamin M.
    Schwartz, Gary
    Eshaghian, Shahrooz
    Stampleman, Laura
    Moss, Robert A.
    Lim, Stephen
    Vescio, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Investigating macrophage function as a mechanism of resistance to daratumumab in relapsed refractory multiple myeloma patients.
    Kambhampati, Swetha
    Wen, Kwun Wah
    Sung, Victoria
    Wong, Sandy Wai Kuan
    Martin, Thomas G.
    Wolf, Jeffrey Lee
    Shah, Nina
    Wiita, Arun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Integrative analysis of mutated genes and mutational processes reveals novel mutational biomarkers in colorectal cancer
    Dashti, Hamed
    Dehzangi, Iman
    Bayati, Masroor
    Breen, James
    Beheshti, Amin
    Lovell, Nigel
    Rabiee, Hamid R.
    Alinejad-Rokny, Hamid
    BMC BIOINFORMATICS, 2022, 23 (01)
  • [49] Integrative analysis of mutated genes and mutational processes reveals novel mutational biomarkers in colorectal cancer
    Hamed Dashti
    Iman Dehzangi
    Masroor Bayati
    James Breen
    Amin Beheshti
    Nigel Lovell
    Hamid R. Rabiee
    Hamid Alinejad-Rokny
    BMC Bioinformatics, 23
  • [50] DNA Mutational Signature in Colorectal Cancer Predicts Mismatch Repair Pathway Status
    Nowak, Jonathan
    Shivdasani, Priyanka
    Agoston, Agoston
    Ogino, Shuji
    Kuo, Frank
    Srivastava, Amitabh
    Dong, Fei
    LABORATORY INVESTIGATION, 2016, 96 : 189A - 189A
12345